{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-323744","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.314326+00:00","generated_at":"2026-06-28T10:58:07.671029+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tango Therapeutics Q3 2021 net loss $19.6M; cash $503.8M funds into H2 2024","bullets":["Net loss of $19.6M ($0.28/share) vs $26.8M ($0.76) in Q3 2020; loss narrowed on revenue change.","Cash, equivalents and marketable securities $503.8M; management expects to fund operations into H2 2024.","Collaboration revenue was $6.8M vs negative $11.3M a year ago, due to Gilead amendment charge in Q3 2020.","TNG908 IND on track for Q4 2021; Phase 1/2 trial initiation expected in H1 2022.","Closed business combination with BCTG Acquisition Corp. and PIPE, yielding gross proceeds of $342M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-323744","json":"https://secwatch.observer/filing/0001193125-21-323744.json","markdown":"https://secwatch.observer/filing/0001193125-21-323744.md","text":"https://secwatch.observer/filing/0001193125-21-323744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312521323744/0001193125-21-323744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312521323744/d256728d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:58:07.671029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}